To address this possibility further, we investigated the effect of GSK-3 inhibition in TKI-resistant CML cells on the expression of ligands for NK cell activating receptors, with a focus on ligands for NKG2D. The gene discussed is NCR1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.